News
IMA
4.720
+1.29%
0.060
Weekly Report: what happened at IMA last week (0914-0918)?
Weekly Report · 4d ago
Weekly Report: what happened at IMA last week (0907-0911)?
Weekly Report · 09/14 10:17
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
Barchart · 09/08 15:30
Weekly Report: what happened at IMA last week (0831-0904)?
Weekly Report · 09/07 10:11
Weekly Report: what happened at IMA last week (0824-0828)?
Weekly Report · 08/31 10:18
Weekly Report: what happened at IMA last week (0817-0821)?
Weekly Report · 08/24 10:18
ImageneBio Initiated at Buy by HC Wainwright & Co.
Dow Jones · 08/21 10:30
ImageneBio Price Target Announced at $28.00/Share by HC Wainwright & Co.
Dow Jones · 08/21 10:30
HC Wainwright & Co. Initiates Coverage On ImageneBio with Buy Rating, Announces Price Target of $28
Benzinga · 08/21 10:20
ImageneBio initiated with a Buy at H.C. Wainwright
TipRanks · 08/21 10:05
Weekly Report: what happened at IMA last week (0810-0814)?
Weekly Report · 08/17 10:19
Weekly Report: what happened at IMA last week (0803-0807)?
Weekly Report · 08/10 10:14
Wedbush Keeps Their Sell Rating on ImageneBio (IMA)
TipRanks · 08/06 17:25
ImageneBio registers to sell 5.77M shares of common stock for holders
TipRanks · 08/05 20:32
ImageneBio files $200M mixed securities shelf
TipRanks · 08/05 20:31
ImageneBio Files Prospectus For Offering $200M Mixed Shelf
Benzinga · 08/05 20:25
ImageneBio, Inc. GAAP EPS of -$0.63
Seeking Alpha · 08/05 19:32
ImageneBio Q2 EPS $(0.63) Beats $(1.05) Estimate
Benzinga · 08/05 12:06
*ImageneBio Sees Cash Runway Funding Planned Ops Into 1Q of 2028 >IMA
Dow Jones · 08/05 12:05
Weekly Report: what happened at IMA last week (0727-0731)?
Weekly Report · 08/03 10:14
More
Webull provides a variety of real-time IMA stock news. You can receive the latest news about ImageneBio through multiple platforms. This information may help you make smarter investment decisions.
About IMA
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.